Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AAM Calls Out Threat Of Consolidation Among Purchasers

Letter To Authorities Accuses Buying Groups And PBMs Of Anticompetitive Activities

Executive Summary

Drug buying groups and pharmacy benefit managers are leaving generic drug producers unable to compete even when they have viable products due to concentration of buyer power, the Association for Accessible Medicines has highlighted.

You may also be interested in...



Increased Transparency Key To Combating Drug Shortages, Says US Industry Alliance

The closure of a Teva manufacturing plant in California has raised concerns around access a number of medicines, something the End Drug Shortages Alliance says could be avoided through increased market transparency.

Biosimilars Forum Welcomes PBM Transparency Act

Senators Maria Cantwell and Chuck Grassley have introduced a bill which would limit pharmacy benefit managers’ ability to engage in “unfair and deceptive” business practices, a move which has been welcomed by the Biosimilars Forum.

Industry Hails Access Implications As FTC Promises PBM Probe

The US FTC’s announcement of an inquiry into PBMs will be music to the ears of the country’s generics and biosimilars industry, which has long called for action on abusive practices that undermine access.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB151757

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel